Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | IMGC936 |
Synonyms | |
Therapy Description |
IMGC936 is an antibody drug conjugate consisting of an antibody that targets Adam9 conjugated to the maytansinoid DM21, which may have potential cytotoxic effects, and inhibit cell proliferation and tumor growth (Cancer Res, 79(13) Suppl., pp. 1533). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
IMGC936 | IMGC-936|IMGC 936 | IMGC936 is an antibody drug conjugate consisting of an antibody that targets Adam9 conjugated to the maytansinoid DM21, which may have potential cytotoxic effects, and inhibit cell proliferation and tumor growth (Cancer Res, 79(13) Suppl., pp. 1533). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04622774 | Phase I | IMGC936 | First-in-Human Study of IMGC936 in Patients With Advanced Solid Tumors | Completed | USA | ITA | ESP | 0 |